| Coupled scRNA-seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer Y Katzenelenbogen, F Sheban, A Yalin, I Yofe, D Svetlichnyy, DA Jaitin, ... Cell 182 (4), 872-885. e19, 2020 | 331 | 2020 |
| Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting R Salomon, H Rotem, Y Katzenelenbogen, A Weiner, N Cohen Saban, ... Nature cancer 3 (3), 287-302, 2022 | 29 | 2022 |
| The transcriptional and regulatory identity of erythropoietin producing cells BK Kragesteen, A Giladi, E David, S Halevi, L Geirsdóttir, OM Lempke, ... Nature medicine 29 (5), 1191-1200, 2023 | 21 | 2023 |
| Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell–dependent regression of glioblastoma T Look, E Puca, M Bühler, D Kirschenbaum, R De Luca, R Stucchi, ... Science Translational Medicine 15 (697), eadf2281, 2023 | 11 | 2023 |
| Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma D Kirschenbaum, K Xie, F Ingelfinger, Y Katzenelenbogen, K Abadie, ... Cell 187 (1), 149-165. e23, 2024 | 10 | 2024 |
| In synergy: optimizing CAR T development and personalizing patient care using single-cell technologies O Barboy, Y Katzenelenbogen, R Shalita, I Amit Cancer discovery 13 (7), 1546-1555, 2023 | 5 | 2023 |
| p16-dependent upregulation of PD-L1 impairs immunosurveillance of senescent cells J Majewska, A Agrawal, A Mayo, L Roitman, R Chatterjee, J Kralova, ... bioRxiv, 2023.01. 30.524522, 2023 | 3 | 2023 |
| Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols O Barboy, A Bercovich, H Li, Y Eyal-Lubling, A Yalin, Y Shapir Itai, ... Nature Cancer, 1-18, 2024 | 1 | 2024 |
| Phospho-proteomic dynamics reveal DNA damage and repair signatures of drug sensitivity G Arad, A Hay-Koren, N Simchi, D Kovalerchik, D Daitchman, A Manor, ... Cancer Research 84 (6_Supplement), 5130-5130, 2024 | | 2024 |
| A novel USP1 inhibitor coupled with a novel proteomic response biomarker for precision oncology therapy I Alchanati, A Morley, A Hay-Koren, F Fierro, G Otonin, S Herman, ... Cancer Research 84 (6_Supplement), 7122-7122, 2024 | | 2024 |
| Abstract B178: Proteomics platform identifies vulnerabilities for specific DNA damage repair drugs G Arad, A Hay-Koren, D Futorian, O Fischman, D Daitchman, O Givton, ... Molecular Cancer Therapeutics 22 (12_Supplement), B178-B178, 2023 | | 2023 |
| Determinants of Response to Anti CD-19 CAR-T Cells for Diffuse Large B-Cell Lymphoma in Pre-Treatment Peripheral Blood Mononuclear Cells Using Single-Cell RNA-Seq R Ram, Y Katzenelenbogen, AG Shapiro, E Winter, O Barboy, M Zada, ... Blood 142, 4829, 2023 | | 2023 |
| Unraveling the Mechanism of Action of Bispecific T-Cell Engagers in B-Cell Acute Lymphoblastic Leukemia Using Advanced Single-Cell Multiomics AG Shapiro, E Winter, Y Moshe, Y Katzenelenbogen, D Jaitin, M Zada, ... Blood 142, 599, 2023 | | 2023 |
| Single-cell transcriptional analysis of multiple myeloma bone marrow aspirates using particle-templated instant partition sequencing (PIPseq) Y Katzenelenbogen, M Zada, R Meltzer, K Fontanez, I Amit Cancer Research 83 (7_Supplement), 84-84, 2023 | | 2023 |
| Methods of treating cancer I Amit, A Weiner, Y Katzenelenbogen, A Yalin, F Sheban US Patent App. 17/876,641, 2022 | | 2022 |
| Method for stabilizing intracellular rna I Amit, Y Ido, D Jaitin, Y Katzenelenbogen, M Lennikov, A Weiner, ... US Patent App. 17/619,722, 2022 | | 2022 |
| SPOTLIGHTS... W Cheng, RG Compton Chem. Eur. J 21, 9282-9285, 2015 | | 2015 |
